MX336225B - Composiciones que comprenden sulfato de salbutamol. - Google Patents

Composiciones que comprenden sulfato de salbutamol.

Info

Publication number
MX336225B
MX336225B MX2014004364A MX2014004364A MX336225B MX 336225 B MX336225 B MX 336225B MX 2014004364 A MX2014004364 A MX 2014004364A MX 2014004364 A MX2014004364 A MX 2014004364A MX 336225 B MX336225 B MX 336225B
Authority
MX
Mexico
Prior art keywords
salbutamol sulphate
compositions
pharmaceutical composition
component consisting
composition
Prior art date
Application number
MX2014004364A
Other languages
English (en)
Other versions
MX2014004364A (es
Inventor
Stuart Corr
Timothy James Noakes
Original Assignee
Mexichem Amanco Holding Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mexichem Amanco Holding Sa filed Critical Mexichem Amanco Holding Sa
Publication of MX2014004364A publication Critical patent/MX2014004364A/es
Publication of MX336225B publication Critical patent/MX336225B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/002—Details of inhalators; Constructional features thereof with air flow regulating means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe una composición farmacéutica libre de tensioactivo. La composición consiste esencialmente de: (a) un componente de fármaco que consiste de sulfato de salbutamol; y (b) un componente propelente que consiste esencialmente de 1,1-difluoroetano (R-152a). También se describe un método para preparar la composición farmacéutica. La composición farmacéutica se puede suministrar utilizando un inhalador de dosis medida (MDI).
MX2014004364A 2011-10-12 2012-10-12 Composiciones que comprenden sulfato de salbutamol. MX336225B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201117621A GB201117621D0 (en) 2011-10-12 2011-10-12 Compositions
PCT/GB2012/052542 WO2013054135A1 (en) 2011-10-12 2012-10-12 Compositions comprising salbutamol sulphate

Publications (2)

Publication Number Publication Date
MX2014004364A MX2014004364A (es) 2014-05-27
MX336225B true MX336225B (es) 2016-01-12

Family

ID=45091933

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004364A MX336225B (es) 2011-10-12 2012-10-12 Composiciones que comprenden sulfato de salbutamol.

Country Status (12)

Country Link
US (1) US9114164B2 (es)
EP (1) EP2766005B1 (es)
JP (1) JP5818290B2 (es)
CN (1) CN103857388B (es)
AU (1) AU2012322453B2 (es)
BR (1) BR112014008609B1 (es)
CA (1) CA2851764C (es)
ES (1) ES2556585T3 (es)
GB (1) GB201117621D0 (es)
MX (1) MX336225B (es)
WO (1) WO2013054135A1 (es)
ZA (1) ZA201402234B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
EP3236967B1 (en) 2014-12-22 2019-10-16 SUDA Pharmaceuticals Ltd Prevention and treatment of metastatic disease in thrombocytotic cancer patients
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
EP3701940A1 (en) 2015-12-04 2020-09-02 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
CN114712337A (zh) * 2016-09-19 2022-07-08 墨西哥氟石股份公司 药物组合物
CA3037080C (en) * 2016-09-19 2021-05-18 Mexichem Fluor S.A. De C.V. Stable pharmaceutical compositions comprising indacaterol and 1,1-difluoroethane (hfa-152a) suitable for use in metered dose inhalers (mdis)
ES2957459T3 (es) 2016-09-19 2024-01-19 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende glicopirrolato
AU2017328910B2 (en) * 2016-09-19 2020-04-09 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
GB2573297A (en) * 2018-04-30 2019-11-06 Mexichem Fluor Sa De Cv Pharmaceutical composition
FR3130554A1 (fr) 2021-12-20 2023-06-23 Aptar France Sas Composition pharmaceutique comprenant du salbutamol
FR3137830A1 (fr) 2022-07-13 2024-01-19 Aptar France Sas Composition pharmaceutique comprenant du salbutamol

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5439670A (en) 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
IE67185B1 (en) 1990-02-02 1996-03-06 Fisons Plc Propellant compositions
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
US7105152B1 (en) * 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
DK0617610T3 (da) * 1991-12-18 1997-10-06 Minnesota Mining & Mfg Suspensionsaerosolformuleringer.
ATE236617T1 (de) 1994-12-22 2003-04-15 Astrazeneca Ab Aerosol-arzneiformulierungen
ES2276736T3 (es) 1995-04-14 2007-07-01 Smithkline Beecham Corporation Inhalador medidor de dosis para propionato de flucticasona.
EP1019020A1 (en) 1997-09-29 2000-07-19 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6103266A (en) 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
PT1102579E (pt) 1998-08-04 2003-07-31 Jago Res Ag Formulacoes de aerossol medicinais
GB2392915B (en) 1999-09-11 2004-04-28 Glaxo Group Ltd Pharmaceutical formulation of fluticasone propionate
US6432415B1 (en) 1999-12-17 2002-08-13 Axrix Laboratories, Inc. Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
CN1144582C (zh) 2000-11-28 2004-04-07 中国药科大学 治疗呼吸系统疾病的无氟里昂药用气雾剂
CN1216600C (zh) * 2002-04-24 2005-08-31 信谊药厂 盐酸左旋沙丁胺醇气雾剂及制备工艺
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0323685D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
WO2006004646A1 (en) 2004-06-28 2006-01-12 Nektar Therapeutics Aerosol formulation comprising nicotine salt
WO2007020204A2 (en) 2005-08-12 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate
GB0915106D0 (en) 2009-08-28 2009-10-07 Glaxo Group Ltd Process

Also Published As

Publication number Publication date
BR112014008609A2 (pt) 2017-04-18
CN103857388A (zh) 2014-06-11
JP5818290B2 (ja) 2015-11-18
AU2012322453A1 (en) 2014-04-17
WO2013054135A1 (en) 2013-04-18
CA2851764C (en) 2017-02-14
CN103857388B (zh) 2016-09-28
EP2766005B1 (en) 2015-11-25
JP2014530231A (ja) 2014-11-17
AU2012322453B2 (en) 2015-06-18
US20140286877A1 (en) 2014-09-25
CA2851764A1 (en) 2013-04-18
ES2556585T3 (es) 2016-01-19
GB201117621D0 (en) 2011-11-23
BR112014008609B1 (pt) 2022-04-12
MX2014004364A (es) 2014-05-27
US9114164B2 (en) 2015-08-25
ZA201402234B (en) 2015-03-25
EP2766005A1 (en) 2014-08-20

Similar Documents

Publication Publication Date Title
MX2014004364A (es) Composiciones que comprenden sulfato de salbutamol.
MX335944B (es) Composiciones que comprenden sulfato de salbutamol.
MX340924B (es) Composiciones farmaceuticas.
UA115139C2 (uk) Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
WO2012016845A3 (en) Pharmaceutical formulation comprising a phosphodiesterase inhibitor
PH12015502593A1 (en) COMPOSITIONS, METHODS and SYSTEMS FOR RESPIRATORY DELIVERY OF THREE OR MORE ACTIVE AGENTS
MX370890B (es) Composición que comprende sulfato de salbutamol.
JP2014528470A5 (es)
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
EP4233874A3 (en) Acetylsalicylic acid for reducing the risk of a thromboembolic event
MX2015015132A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
IN2014DN01619A (es)
WO2014007770A3 (en) Inhalation compositions comprising corticosteroid and sorbitol
WO2013104892A8 (en) Application of high dose compounds via inhalation
WO2014007772A3 (en) Inhalation compositions comprising glucose anhydrous
MX2012004338A (es) Formulaciones mejoradas.
PH12014502662A1 (en) Novel dosage form and formulation of abediterol
WO2014007781A3 (en) Inhalation compositions
MD20140131A2 (ro) Doză şi formă preparativă nouă pentru inhalare care cuprinde aclidiniu
CY1117596T1 (el) Φαρμακευτικeς συνθeσεις αερολyματος φορμοτερολης και διπροπιονικης βεκλομεθαζονης
WO2014007771A3 (en) Inhalation compositions comprising muscarinic receptor antagonist
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
MY179794A (en) Compound composition for inhalation used for treating asthma
MX2015015150A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.